Arvinas (NASDAQ:ARVN) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Arvinas (NASDAQ:ARVN) in a research note released on Friday morning,Benzinga reports.

Several other equities research analysts have also recently weighed in on the company. BTIG Research initiated coverage on Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target for the company. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. Oppenheimer decreased their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.45.

Arvinas Stock Down 2.1 %

NASDAQ ARVN opened at $18.70 on Friday. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.00 and a beta of 1.88. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08. The stock has a fifty day simple moving average of $19.75 and a 200 day simple moving average of $23.67.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Braidwell LP boosted its holdings in shares of Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after buying an additional 767,242 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in Arvinas in the third quarter worth about $9,989,000. JPMorgan Chase & Co. boosted its stake in Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after acquiring an additional 367,343 shares during the last quarter. FMR LLC grew its position in shares of Arvinas by 7.6% during the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after acquiring an additional 204,317 shares during the period. Finally, Wasatch Advisors LP grew its position in shares of Arvinas by 58.3% during the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares during the period. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.